TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced adenocarcinoma of lung, measurable disease~* Non-smoker, or former light (less than 10 pack years and stopped at least 15 years); OR~* patients with known EGFR activating mutation regardless of smoking status~* ECOG(Eastern Cooperative Oncology Group) 0-1.~Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy~Exclusion Criteria:~* Active brain metastases~* Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy.~* known EGFR wild type NSCLC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
- Cohort B (Type: EXPERIMENTAL): Dacomitinib in patients with HER2 mutated or amplified NSCLC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Clinical symptoms:~   * Angina \< 12 h persistent Angina \> 30 min.~2. ECG-Criteria:~   * ST-elevation \> 1mm in ≥ 2 extremity leads~  * ST-elevation \> 2mm in ≥ 2 contiguous anterior leads~3. Informed consent~Exclusion Criteria:~1. No consent~2. Pregnancy~3. Allergy against abciximab, ASA or heparin~4. Active peptic ulcus ventriculi or duodeni~5. Active non-superficial bleeding~6. Major surgical intervention, intracerebral interventions, puncture central artery \< 4 weeks~7. Active internal bleeding~8. Cerebrovascular complications \< 2 years~9. Known coagulation disorders, thrombocytopenia~10. Arteriovenous malformations or aneurysms~11. Severe Liver or renal dysfunction~12. Severe untreated hypertension~13. Active vasculitis~14. Previous thrombolysis \< 12 h

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between the ages of 7 and 18 years, diagnosed with Chronic Rhinitis and nasal stuffiness for at least 3 month duration.~Exclusion Criteria:~* Children with immunodeficiency, cystic fibrosis, acute or subacute symptoms, signs of bacterial infection, and/or those who are unable to cooperate with testing will be excluded. Children with documented use of the study medication in the month before evaluation and during period of symptoms will also be excluded.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is provided by the sponsor and is identical in composition to the treatment only lacking active drug.
- Guaifenesin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed ICF (Informed Consent Form)~* Patient-reported history of DED in both eyes~* Current use of OTC (over-the-counter) and/or artificial tears for dry eye symptoms~* Ability and willingness to follow instructions, including participation in all study assessments and visits~Exclusion Criteria:~* Women who are pregnant, nursing or planning a pregnancy~* Unwillingness to submit a urine pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control~* Clinically significant slit-lamp findings or abnormal lid anatomy at screening~* Ocular/periocular malignancy~* History of herpetic keratitis~* Active ocular allergies or ocular allergies that may become active during the study period~* Ongoing ocular or systemic infection at screening or baseline~* Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study~* Use of topical Cyclosporine A or Liftigrast within 2 months prior to screening~* Intraocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period~* Presence of uncontrolled systemic diseases~* Presence of known allergy and/or sensitivity to the study drug or its components~* Randomized in a previous CyclASol trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CyclASol Ophthalmic Solution (Type: EXPERIMENTAL): Cyclosporine A solution in vehicle
- Vehicle Ophthalmic solution (Type: PLACEBO_COMPARATOR): Vehicle only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has ocular hypertension or glaucoma in both eyes~* Requires IOP-lowering therapy in each eye~Exclusion Criteria:~* Active or recurrent eye disease that would interfere with interpretation of study data in either eye~* History of any eye surgery or laser in either eye within 6 months~* Required chronic use of other eye medications during the study~* Anticipated wearing of contact lenses during the study.~* Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bimatoprost/timolol formulation A (Type: EXPERIMENTAL): One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
- bimatoprost/timolol fixed combination ophthalmic solution (Type: ACTIVE_COMPARATOR): One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years and older at index date~* Diagnosis of MM~* Measurable disease according to IMWG criteria~* ECOG performance status ≤2~* Refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 treatment (ie, triple-class refractory \[TCR\])~* At least 1 treatment following their TCR eligibility~Exclusion Criteria:~* Acute plasma cell leukemia~* Amyloidosis~* Smoldering MM~* Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)~* Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ~* Administration with an investigational drug within 30 days prior to index

- Gender: ALL
- Minimum Age: 18 Weeks
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elranatamab (Type: None): Patients treated with elranatamab from the MagnetisMM-3 trial
- Standard of care (Type: None): Patients treated with standard-of-care therapies from real-world data sources

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Male or female with a body weight ≥10 to 40 kg~* Patients suffering from acute uncomplicated Plasmodium falciparum malaria~* Malaria diagnosis confirmed by a positive blood smear with asexual forms of Plasmodium falciparum (i.e., identification of asexual parasite count ≥1,000 to 250,000 per mm3)~* Ear temperature 37.5°C or a history of fever within the last 48 hours~* Haemoglobin 7g/100ml~* Written informed consent and written consent from parents/guardian for children below age of consent (verbal consent in presence of literate witness is required for illiterate patients or parents/guardians).~Exclusion Criteria:~Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment (defined according to WHO Recommendations Malaria Control Today, RBM Working Document, March 2005, see Appendix 2)~* Patients with known hypersensitivity or allergy to artemisinin derivatives or mefloquine or mefloquine chemically related compounds (for example quinine and quinidine)~* Patients who had received quinine or any artemisinin derivatives within 12 hours prior to study start~* Patients who had received any other adequate antimalarial drug therapy including antibiotics which might be active against malaria infection within 1 week prior to study start~* Patients who had received investigational (unlicensed) drugs as well as mefloquine within 30 days prior to study start~* Patients with known history of psychiatric disorders~* Patients with known history of cardiac diseases and arrhythmia~* Patients with known sickle cell disease~* Patients with clinical signs of or laboratory evidence for any other severe hepatic, renal, pulmonary, cardiac, metabolic, psychiatric, cancer or haematologic diseases~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting with transfusion-related IOL as shown by a SF level of ≥ 1000 ng/mL at start of study~* History of transfusion \>20 international units or 100 mL/kg of red blood cells~* Underlying transfusion-dependent illness:~  * AA: Clinically diagnosed AA with bone marrow confirmation of the diagnosis~* Age ≥ 18 years, male or female~* Written informed consent obtained from patient prior to any screening procedures.~Exclusion Criteria:~* Patients with serum creatinine \> ULN or with significant proteinuria as indicated by a urinary protein/creatinine ratio (UPCR) ≥ 1.0 mg/mg in a non-first void urine sample at baseline. If serum creatinine is found to be \> ULN or UPCR is found to be ≥ 1 mg/mg the test can be repeated after 1 month.~* Creatinine Clearance \<40 ml/min~* Patients with other than AA transfusion-dependent underlying illnesses~* Patients with a previous history of clinically relevant ocular and/or auditory toxicity related to iron chelation~* Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:~* history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding~* history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection~* history of pancreatic injury or pancreatitis; indications of impaired pancreatic function/injury as indicated by abnormal lipase or amylase~* history or presence of impaired renal function as indicated by creatinine or blood urea nitrogen (BUN) values equal or above ULN~* history of urinary obstruction or difficulty in voiding~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desferasirox (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 16 years of age or older~* Disease history of at least six months meeting at least 4 out of the 11 American College of Rheumatology (ACR) criteria for SLE~* Active SLE with at least one British Isles Lupus Assessment Group (BILAG) flare A or B at screening requiring a change in the dose of corticosteroids~* Positive antinuclear antibody (ANA) or anti-double-stranded deoxyribonucleic acid (dsDNA) at screening~* Female subjects must be willing to avoid pregnancy by using an adequate method of contraception for 4 weeks prior to Study Day 1, during the trial and 24 weeks after the last dose of study medication~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Active moderate to severe glomerulonephritis (kidney impairment) as defined in the protocol~* Active central nervous system SLE deemed to be severe/progressive and/or associated with significant cognitive impairment leading to inability to provide informed consent and/or comply with the protocol~* Previous treatment with rituximab, abatacept, or belimumab~* History of demyelinating disease such as multiple sclerosis (MS) or optic neuritis~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atacicept 75 mg (Type: EXPERIMENTAL): None
- Atacicept 150 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xylitol for Chronic Sinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients above the age of 18~* History of chronic rhinosinusitis history who had undergone bilateral endoscopic sinus surgery to include at a minimum maxillary antrostomy and anterior ethmoidectomy.~* Continued chronic sinusitis that is refractory to medical therapy after surgical intervention~Exclusion Criteria:~* Patients under age of 18~* Non-English speaking~* History of immunodeficiency disease~* Cystic fibrosis~* Primary ciliary dyskinesia~* History of granulomatous disease~* Active smoker~* Treatment with antifungal medications~* Use of antifungal medications~* Acute bacterial infection requiring antibiotics~* Active pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Xylitol (Type: EXPERIMENTAL): This arm will evaluate the effect of topical xylitol therapy on biofilm production with the use of PCR bacterial sequencing before and after medical intervention.
- Control (Type: ACTIVE_COMPARATOR): This arm is the standard of care saline irrigation solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Administration of Pregabalin for Pain After Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. American Society of Anesthesia physical status class I \& II~2. Age \> 20 and \< 70 years~3. Robot- assisted endoscopic thyroidectomy~Exclusion Criteria:~1. Known or suspected allergy, sensitivity, or contraindication to pregabalin or any of the standardized medications~2. Body mass index ≥ 40 kg/m2~3. History of seizure disorder~4. Current therapy with pregabalin, gabapentin, or any opioid~5. Any other physical or psychiatric condition which may impair their ability to cooperate with post-operative study data collection~6. Insulin-dependent diabetes mellitus~7. Renal insufficiency (estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2)

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later
- Pregabalin (Type: EXPERIMENTAL): Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aleglitazar in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age;~* type 2 diabetes, diagnosed \>=1 month of screening;~* either drug-naive, or pretreated with a maximum of 2 oral antihyperglycemic agents at submaximal doses;~* HbA1c \<=10.0% at screening, and 7.0-10.0% at pre-randomisation visit.~Exclusion Criteria:~* type 1 diabetes;~* currently or previously treated with insulin, a thiazolidinedione, or a dual Peroxisome Proliferator Activated Receptor (PPAR) agonist;~* clinically significant cardiovascular disease;~* Congestive Heart Failure (CHF) New York Heart Association (NYHA) 3-4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Actos (Type: ACTIVE_COMPARATOR): None
- Aleglitazar 1 (Type: EXPERIMENTAL): None
- Aleglitazar 2 (Type: EXPERIMENTAL): None
- Aleglitazar 3 (Type: EXPERIMENTAL): None
- Aleglitazar 4 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients,~* Aged \> than equal to 18 years,~* Patient presenting with an OHT or OAG with an IOP � 21 mmHg,~* Patient currently treated with ophthalmic beta-blockers monotherapy and requiring a change of the ophthalmic medication due to insufficient response to treatment,~Exclusion Criteria:~* Patient currently treated by or having received within the last month any ophthalmic hypotensive agent other than a beta-blocker,~* Patient presenting any contraindication to latanoprost or timolol,~* Patient with history of asthma, obstructive broncho-pneumopathy, sinusal bradycardia (pulse rate \< 60 bpm), auriculo-ventricular block, cardiac insufficiency, Raynaud disease or any other condition that would preclude the patient from taking the prescribed medication,~* Patient with known intolerance to benzalkonium chloride or any excipient contained in the trial treatment,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): None
- Procedure (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers with an intact thyroid gland~* Patients with nontoxic/subtoxic nodular goiter confirmed by ultrasonography~* Patients with toxic nodular goiter~* Patients with Graves' disease~Exclusion Criteria:~* Treatment with drugs that alter thyroid function or size (the last 3 months prior to inclusion)~* Prior 131I treatment~* Alcohol, medicine or drug abuse~* Pregnancy or lactation~* No safe contraception~* Participation in another clinical trial~* Allergic reaction towards rhTSH~* Fine needle biopsy without valid diagnostic criteria for benign disease~* Suspicion of malignancy, increased ionized serum calcium and/or serum calcitonin~* Incontinence~* Physically or psychic condition that hinders corporation~* Ischemic attack up till 3 months before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete